An evaluation of the United Kingdom National Osteoporosis Society position statement on the use of peripheral dual-energy X-ray absorptiometry

Osteoporosis International

Volumn 15, Issue 6, 2004, Pages 497-504

  Patel, Rajesh ^a   Blake, Glen M ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density; Osteoporosis; Peripheral dual energy X ray absorptiometry

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; BONE DENSITY; BONE MINERAL; COLLES FRACTURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP FRACTURE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; META ANALYSIS; NORMAL DISTRIBUTION; OSTEOPOROSIS; PRIORITY JOURNAL; SCORING SYSTEM; UNITED KINGDOM; VERTEBRA FRACTURE;

EID: 3042588413     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1565-2     Document Type: Article

References (40)

1. Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-289
2. Ray NF, Chan JK, Thamer M, Melton LJ (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
3. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int 7:390-406
4. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
5. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077-2082
6. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
7. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352
8. Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
9. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk 0reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124
10. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
11. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344:1434-1441
12. Delmas PD, Ensrud KE, Adachi JD et al (2001) Efficacy of raloxifene on vertebral fracture risk in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
13. Royal College of Physicians (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. RCP, London
14. US Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Arch Intern Med 137:526-528
15. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
16. WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No. 843. World Health Organization, Geneva
17. National Osteoporosis Society (2002) Position statement on the reporting of dual energy X-ray absorptiometry (DXA) bone mineral density scans. NOS, Bath, England
18. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
19. Miller PD, Siris ES, Barrett-Connor E et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222-2230
20. Augat P, Fuerst T, Genant HK (1998) Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 8:299-310
21. Blake GM, Wahner HW, Fogelman I (1999) The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. Martin Dunitz, London, pp 89-105
22. National Osteoporosis Society (2001) Position statement on the use of peripheral X-ray absorptiometry in the management of osteoporosis. NOS, Bath, England
23. Lu Y, Genant HK, Shepherd J et al (2001) Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16:901-910
24. Trumpler RJ, Weaver HF (1962) Statistical astronomy. Dover, New York, pp 42-68
25. Blake GM, Patel R, Knapp KM, Fogelman I (2003) Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res 18:1955-1963
26. Blake GM, Fogelman I (2001) Peripheral or Central Densitometry: does it matter which we use? J Clin Densitom 4:83-96
27. Kelly TL (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5[Suppl 2]:S249
28. Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489
29. Cooper C, Atkinson EJ, Jacobsen SJ et al (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiology 137:1001-1005
30. Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407-413
31. Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611-617
32. Torgerson DJ, Dolan P (2000) The cost of treating osteoporotic fractures in the United Kingdom female population (letter to the editor). Osteoporos Int 11:511-512
33. Grampp S, Genant HK, Mathur A et al (1997) Comparisons of non-invasive bone mineral measurements in assessing age-related bone loss, fracture discrimination and diagnostic classification. J Bone Miner Res 12:697-711
34. Faulkner KG, VonStetton E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343-350
35. Miller PD (2000) Controversies in bone mineral density diagnostic classifications. Calcif Tissue Int 66:317-319
36. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077-2082
37. Bouxsein ML, Parker RA, Greenspan SL (1999) Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporos Int 10:505-509
38. Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrin Met 87(10):4528-4535
39. National Osteoporosis Society (2001) Position statement on the use of quantitative ultrasound in the management of osteoporosis. NOS, Bath, England
40. Blake GM, Fogelman I (1997) Interpretation of bone densitometry studies. Semin Nucl Med 27:248-260